Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients
- 1 May 1998
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 20 (3), 567-580
- https://doi.org/10.1016/s0149-2918(98)80066-0
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cost Comparison of β2‐Agonist Bronchodilators Used in the Treatment of AsthmaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1995
- Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country.Archives of Disease in Childhood, 1995
- The Episode-Free Day as a Composite Measure of EffectivenessPharmacoEconomics, 1993
- Cost Effectiveness of Inhaled Corticosteroid plus Bronchodilator Therapy versus Bronchodilator Monotherapy in Children with AsthmaPharmacoEconomics, 1993
- The Cost of AsthmaPharmacoEconomics, 1993
- An Economic Evaluation of Asthma in the United StatesNew England Journal of Medicine, 1992
- Variations in asthma hospitalizations and deaths in New York City.American Journal of Public Health, 1992
- The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderlyArchives of Internal Medicine, 1990
- Clinical economics. A guide to the economic analysis of clinical practicesJAMA, 1989
- Poverty, race, and hospitalization for childhood asthma.American Journal of Public Health, 1988